Osielsko

Vitiligo is a long-term autoimmune condition where the immune system mistakenly attacks skin cells that produce pigment, leading to patches of skin that lose color. This study focuses on adults with nonsegmental vitiligo, where symmetrical patches of depigmentation appear on both sides of the body. The trial aims to evaluate the safety, effectiveness, and tolerability of zasocitinib in treating this condition in adults aged 18 to 75 years. Participants will receive either zasocitinib capsules or placebo capsules that look identical but contain no medicine. The treatment period lasts up to one year (52 weeks). Those initially receiving placebo will switch to zasocitinib after about six months. During the study, participants will visit the clinic 11 times for treatment and monitoring. Throughout the trial, researchers will assess how well participants respond to treatment by measuring improvement in facial vitiligo using a standardized scoring index at baseline and after 24 weeks. Additional evaluations include safety monitoring and adherence to the study procedures. Participants will undergo clinical assessments, laboratory tests, and provide informed consent before starting the trial.

The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children and adolescents (6 to \<18 Years Old) with moderate atopic dermatitis.

Researchers are evaluating the effectiveness and safety of ruxolitinib cream in children aged 6 to under 12 years with nonsegmental vitiligo, a condition causing skin depigmentation. This phase 3 study focuses on children who have vitiligo affecting specific body areas, including the face and other parts, with certain minimum involvement percentages required for enrollment. Participants will be randomly assigned to receive either ruxolitinib cream or a matching vehicle cream, both applied topically as a thin film twice daily to affected areas. The study is double-blinded, meaning neither the participants nor the researchers know who receives which cream. Treatment will continue with regular assessments to monitor progress and safety. During the study, children will have their vitiligo area measured using the Facial Vitiligo Area Scoring Index (F-VASI) to assess improvement, with the main goal being at least a 75% improvement by week 24. Participants must stop all other vitiligo treatments during the study and will be closely monitored for safety and adherence through scheduled visits and evaluations. The total body vitiligo area must be 10% or less for participation.

Researchers are evaluating the safety, effectiveness, and tolerability of upadacitinib in adolescents and adults with severe alopecia areata (AA), a condition where the immune system attacks hair follicles causing hair loss on the head, face, or other body parts. This phase 3 study involves about 1500 participants worldwide and compares upadacitinib to a placebo to assess treatment impact on severe AA. Participants are randomly assigned to one of three groups receiving either upadacitinib or placebo oral tablets once daily for up to 160 weeks. There is a chance for re-randomization at weeks 24 and 52 based on Severity of Alopecia Tool (SALT) scores. Those completing initial studies may join an extension study to receive upadacitinib for up to an additional 108 weeks. Follow-up occurs for 30 days after the last dose. Throughout the study, participants attend regular visits at hospitals or clinics for medical assessments, blood tests, side effect monitoring, and questionnaires. Researchers measure the percentage of participants achieving a SALT score of 20 or less at week 24 and track adverse events up to 164 weeks. The study may involve a higher treatment burden compared to usual care due to frequent visits and evaluations.

This research focuses on participants with Hidradenitis Suppurativa (HS) who have previously taken part in specific Incyte-sponsored clinical trials of povorcitinib. The study is a Phase 3b rollover trial designed to continue monitoring these individuals to gather further information on the treatment. It aims to evaluate the safety of povorcitinib over an extended period, including the proportion of participants experiencing treatment-emergent adverse events for up to about three years. Participants will continue taking the study drug povorcitinib orally as specified by the study protocol. This rollover study includes individuals who completed the treatment period in the parent studies without safety or tolerability issues and who showed clinical benefit from povorcitinib. During this study, participants will follow the protocol-defined dosing and procedures while avoiding pregnancy or fathering children as required. Throughout the study, participants will attend scheduled visits and assessments to monitor their health and treatment effects. Researchers will track adverse events and adherence to the treatment plan. The study involves ongoing evaluation for up to approximately three years to ensure safety and collect important long-term data on povorcitinib use in this group of patients with HS.